拜玛林制药
BMRN
54.68
-1.37
-2.44%
拜玛林制药
US · BMRN
#1379 按市值排名
上市于 1970
54.68
-1.37
-2.44%
实时 - 追踪5344个代码 - 心跳于570秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了6家。
- 机构持股总比例下降了0.1个百分点。
机构持股
- 机构持股比例
- 102.45% -0.12pp
- 机构数量
- 674 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund71.95%
Hedge Fund18.67%
Sovereign Wealth Fund4.25%
Public Company2.10%
VC/PE Fund1.92%
Government Pension Fund1.91%
Private Company0.73%
Insurance Company0.66%
Individual/Insider0.40%
主要股东 截至 2026-06-30
BlackRock
10.56% · 20.45M 股
Dodge & Cox
7.67% · 14.84M 股
PRIMECAP Management Company
7.33% · 14.19M 股
Vanguard Capital Management, LLC
5.15% · 9.97M 股
Vanguard Portfolio Management, LLC
4.47% · 8.65M 股
Norges Bank Investment Management
4.24% · 8.21M 股
State Street Global Advisors
4.03% · 7.80M 股
Viking Global Investors LP
3.93% · 7.62M 股
Vestal Point Capital, LP
3.11% · 6.03M 股
AQR Capital Management
2.93% · 5.68M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 30次买入 · 20次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Richard Meier | Lead Independent Director | 0.07% |
| Elaine Heron | Independent Director | 0.05% |
| Brian Mueller | Chief Financial Officer | 0.04% |
| George Davis | Chief Legal Officer | 0.03% |
| Alexander Hardy | Chief Executive Officer | 0.03% |
| C. Guyer | Chief Technical Officer of Manufacturing & Technical Operations | 0.03% |
| Gregory Friberg | Executive VP and Chief Research & Development Officer | 0.02% |
| David E. Pyott | Independent Director | 0.02% |
| Robert Hombach | Independent Director | 0.02% |
| Elizabeth Anderson | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Gregory Friberg | Executive VP and Chief Research & Development Officer | Sale to Issuer | -4,086 | $60.00 |
| 2026-09-09 | Robert Plenge | Independent Director | Other Acquisition | +6,140 | -- |
| 2026-09-01 | George Davis | Chief Legal Officer | Open Market Disposition | -17,557 | $66.28 |
| 2026-06-01 | Mark Enyedy | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Ian T. Clark | Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Willard Dere | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Timothy Walbert | Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Maykin Ho | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Robert Hombach | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Athena Countouriotis | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Elizabeth Anderson | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Barbara Bodem | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-05-19 | Cristin Hubbard | Executive Vice President | Sale to Issuer | -2,318 | $50.20 |
| 2026-05-06 | Gregory Friberg | Executive VP and Chief Research & Development Officer | Open Market Disposition | -3,281 | $53.85 |
| 2026-03-17 | George Davis | Chief Legal Officer | Sale to Issuer | -1,273 | $56.05 |
| 2026-03-16 | Alexander Hardy | Chief Executive Officer | Sale to Issuer | -4,252 | $56.05 |
| 2026-03-16 | Brian Mueller | Chief Financial Officer | Sale to Issuer | -2,117 | $56.05 |
| 2026-03-16 | Gregory Friberg | Executive VP and Chief Research & Development Officer | Sale to Issuer | -1,629 | $56.05 |
| 2026-03-16 | Cristin Hubbard | Executive Vice President | Sale to Issuer | -1,245 | $56.05 |
| 2026-03-16 | C. Guyer | Chief Technical Officer of Manufacturing & Technical Operations | Sale to Issuer | -1,693 | $56.05 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
拜玛林制药 讨论区 0 条评论